Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma

Autor(es)

Ji H. Yang ^[1] ; Rui M. B. Maciel ^[2] ; Claudia C. D. Nakabashi ^[3] ; Carolina C. P. S. Janovsky ^[4] ; Rosalia P. Padovani ^[5] ; Danielle Macellaro ^[6] ; Cléber P. Camacho ^[7] ; Akemi Osawa ^[8] ; Jairo Wagner ^[9] ; Rosa Paula M. Biscolla ^[10]

Afiliação do(s) autor(es)

^[1] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

^[2] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

^[3] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

^[4] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

^[5] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

^[6] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

^[7] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

^[8] Hospital Israelita Albert Einstein. Departamento de Imagem - Brasil

^[9] Hospital Israelita Albert Einstein. Departamento de Imagem - Brasil

^[10] Universidade Federal de São Paulo. Departamento de Medicina, Escola Paulista de Medicina. Divisão de Endocrinologia - Brasil

• Tipo de documento: Artigo Científico
• Fonte: ARCHIVES OF ENDOCRINOLOGY METABOLISM; v. 61, n. 5, p. 416-425, 2017-09-18.

Resumo

ABSTRACT Objective To evaluate the clinical utility of 18F-FDG PET/CT in patients with high-risk DTC. Subjects and methods Single-center retrospective study with 74 patients with high-risk differentiated thyroid cancer (DTC), classified in 4 groups. Group 1: patients with positive sTg or TgAb, subdivided in Group 1A: negative RxWBS and no foci of metastases identified at conventional image (n = 9); Group 1B: RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level (n = 13); Group 2: patients with histological findings of aggressive DTC variants (n = 21) and Group 3: patients with positive RxWBS (n = 31). Results 18F-FDG PET/CT identified undifferentiated lesions and helped restage the disease in groups 1B and 2. The scan helped guide clinical judgment in 9/13 (69%) patients of group 1B, 10/21 (48%) patients of group 2 and 2/31 (6%) patients of group 3. There was no clinical benefit associated with group 1A. 18F-FDG PET/CT was associated with progressive disease. Conclusion 18F-FDG PET/CT is a useful tool in the follow-up of patients with high-risk DTC, mainly in the group of RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level and in those with aggressive DTC variants. Additionally, this study showed that 18F-FDG PET/CT was associated with progression and helped display undifferentiated lesions guiding clinical assessments regarding surgeries or expectant treatments. (AU)

• Processo FAPESP: 06/60402-1 - Carcinoma medular da tiróide: revisitação à clínica, à biologia molecular, à bioquímica e à biologia do desenvolvimento depois dos achados da genética molecular
• Beneficiário: Rui Monteiro de Barros Maciel
• Modalidade de apoio: Auxílio à Pesquisa - Temático